PubMed COVID-19 Clinical Care

OBJECTIVES: Telehealth use flourished during the COVID-19 pandemic, as older patients faced obstacles to seeking in-person care. Heavy reliance on telehealth may continue post-pandemic, due to increased Medicare investments in its use. However, it is

In the recent past several vaccines were developed to combat the COVID-19 disease. Unfortunately, the protective efficacy of the current vaccines has been reduced due to the high mutation rate in SARS-CoV-2. Here, we successfully implemented a

No abstract

No abstract

Coronaviruses are a well-established and deadly group of viruses that cause illness in both humans and animals. The novel type of this virus group, named COVID-19, was firstly reported in December 2019, and, with the passage of time, coronavirus has

The safety and immunogenicity of a protein-based tetravalent vaccine SCTV01E that contains spike protein ectodomain (S-ECD) of Alpha, Beta, Delta and Omicron BA.1 are assessed and compared with bivalent protein vaccine SCTV01C (Alpha and Beta

The SARS-CoV-2 (COVID-19) pandemic and implementation of stay-at-home orders led to changes in the daily lives of children. Subsequently, there have been reports of increases in pediatric violent traumatic injuries. This review summarizes the

The COVID-19 pandemic has impacted the world that was not previously conceivable. In early 2020, hospitals on all continents were overwhelmed with patients afflicted with this novel virus, with unanticipated mortality worldwide. The virus has had a

CONCLUSIONS: We found that a QI sepsis initiative was associated with an increase in the proportion of patients who received BS antibiotics in the ED, and a small absolute increase in associated subsequent MDR infections, with no apparent effect on

INTRODUCTION: On 4 April 2023, the United States Food and Drug Administration issued an emergency use authorization for the use of vilobelimab (Gohibic^(TM)) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of